Cetuximab Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting cetuximab clinical trials across 2 countries. Studies span Phase 2. Top locations include Chengdu, Sichuan, China, Hangzhou, Zhejiang, China, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Cetuximab Trials at a Glance

6 actively recruiting trials for cetuximab are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Chengdu, Hangzhou, and Beijing. Lead sponsors running cetuximab studies include Zhejiang University, Chang Gung Memorial Hospital, and Tianjin Medical University Cancer Institute and Hospital.

Browse cetuximab trials by phase

Treatments under study

About Cetuximab Clinical Trials

Looking for clinical trials for Cetuximab? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cetuximab trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cetuximab clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Colorectal, CancerKRAS G12C Mutant Advanced Solid TumorsFulzerasib+1 more
Zhejiang University40 enrolled1 locationNCT07581912
Recruiting
Phase 2

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Colorectal, CancerBRAF V600ESintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting
Phase 2

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Colorectal NeoplasmsBRAFCetuximab+2 more
Zhejiang University70 enrolled1 locationNCT07257653
Recruiting
Phase 2

Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Xinqiao Hospital of Chongqing96 enrolled1 locationNCT06279351
Recruiting
Phase 2

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

Colo-rectal CancerCapecitabineCetuximab
West China Hospital150 enrolled1 locationNCT05022030
Recruiting

Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)

Metastatic colorectal cancer receiving third-line therapy with cetuximab
Chang Gung Memorial Hospital30 enrolled1 locationACTRN12612000052831